Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-15 3:35 pm Sale | 2025-03-31 | 13G | Evaxion Biotech A/S EVAX | ARMISTICE CAPITAL LLC | 310,441 4.990% | -328,888 (-51.44%) | Filing History |
| 2025-02-14 5:44 pm Purchase | 2024-12-31 | 13G | Evaxion Biotech A/S EVAX | ARMISTICE CAPITAL LLC | 639,329 9.990% | 639,329 (New Position) | Filing History |
| 2025-02-03 4:15 pm Purchase | 2025-01-31 | 13G | Evaxion Biotech A/S EVAX | Merck & Co. Inc. MRK | 63,004,142 19.960% | 63,004,142 (New Position) | Filing History |
| 2024-11-14 3:29 pm Unchanged | 2024-11-14 | 13G | Evaxion Biotech A/S EVAX | ARMISTICE CAPITAL LLC | 0 0.000% | 0 (Unchanged) | Filing |
| 2024-11-06 4:09 pm Unchanged | 2024-11-06 | 13G | Evaxion Biotech A/S EVAX | Merck & Co. Inc. MRK | 0 0.000% | 0 (Unchanged) | Filing |
| 2024-01-23 3:29 pm Unchanged | 2024-01-23 | 13G | Evaxion Biotech A/S EVAX | Merck & Co. Inc. MRK | 0 0.000% | 0 (Unchanged) | Filing |